Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage To be used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.
Marketing Status Prescription; Discontinued
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 48087-0113; 69238-1013; 49452-7652; 66887-004; 63629-2125; 0591-2114; 63629-2124; 0832-1120; 65089-0050; 63629-8455; 16714-967; 0603-7831; 0591-2363; 42667-5511; 49884-418; 82393-113; 24979-078; 76420-684; 43598-304; 38779-2598; 66887-001; 44132-008; 0832-1121; 64025-0010; 22552-0009; 0023-5990; 0051-8462; 38779-0163; 60870-0251; 45802-754; 70492-002; 51927-1026; 0591-2924; 71589-013; 0591-2921; 0591-2926; 51552-0029; 62332-488; 16714-968; 0245-0872; 44132-006; 0245-0871; 45802-366; 49452-7657; 0591-2925; 0051-8425; 76420-687; 68382-362; 76420-686; 0591-3216; 60592-721; 24979-130; 12875-8248; 45802-610; 76003-1083; 38779-2936; 0009-0074; 49884-510; 68180-943; 43647-568; 0051-8450; 0802-8068; 71589-011; 62991-2150; 69097-363; 0023-5992; 0009-5020; 0591-3524; 69339-158; 43742-1242; 76420-685; 70700-112; 68180-941; 63481-183; 43742-1436; 43742-0677; 63629-2352; 76420-699; 51552-0564; 16714-969; 0591-3217; 45802-281; 62332-552
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Korsakoff's syndrome17.03.02.008; 14.12.02.007; 19.20.05.002--Not Available
Prostatic dysplasia21.04.01.007--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Peripheral artery thrombosis24.01.02.0100.002078%Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Hepatocellular carcinoma09.04.02.010; 16.07.02.005--Not Available
Peripheral venous disease24.04.02.0220.001188%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Frustration tolerance decreased19.04.02.0160.000891%Not Available
Acne conglobata23.02.01.0080.000891%Not Available
Blood testosterone abnormal13.10.05.0010.005047%Not Available
Catheterisation cardiac13.14.07.0030.002969%Not Available
Cavernous sinus thrombosis24.01.04.015; 17.08.03.005; 11.01.03.0110.000594%Not Available
Cerebral artery thrombosis24.01.04.008; 17.08.01.0260.000891%Not Available
Coronary artery embolism24.01.05.007; 02.02.01.0130.000891%Not Available
Fear of disease19.06.03.0070.000594%Not Available
Haemorrhagic infarction24.04.02.0080.000594%Not Available
Mesenteric vein thrombosis07.15.02.013; 24.01.08.0040.004156%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.015--Not Available
Muscle hypertrophy15.05.03.0300.000155%Not Available
Myocardial fibrosis02.04.02.0160.000310%Not Available
Ovarian hyperfunction21.11.02.016; 05.05.01.0190.001781%Not Available
Penile size reduced21.12.01.0180.000594%Not Available
Purulent discharge11.01.08.061; 08.01.03.0760.000594%Not Available
Respiratory rate increased13.15.01.0040.000594%Not Available
Wolff-Parkinson-White syndrome02.03.01.0160.000594%Not Available
Atrial thrombosis24.01.05.005; 02.01.01.013--Not Available
Silent myocardial infarction24.04.04.025; 02.02.02.0220.000891%Not Available
Testis discomfort21.13.01.0110.000891%Not Available
Medical observation13.15.01.0440.001484%Not Available
The 25th Page    First    Pre   25 26    Next   Last    Total 26 Pages